A treatment-period difference can be misleading if a similar difference was present before treatment. This DSIP study explicitly raised that issue. Primary study
What was studied
Chronic insomnia patients underwent polysomnography in a double-blind crossover comparison of DSIP and placebo over four nights. Several waking measures improved numerically without significant treatment comparisons. Differences in NREM and stage-two sleep were significant between conditions, but corresponding differences already existed at baseline. Slow-wave and REM sleep were not modified. The authors judged clinical benefit limited. Primary report
Our appraisal: an endpoint difference is not automatically a treatment effect
The starting point matters because it helps distinguish a pre-existing pattern from a change attributable to an intervention. Simply comparing the final values can exaggerate an effect when the conditions were already separated beforehand.
Crossover studies require particular attention to periods and sequence. Each participant can serve as a control, but adaptation to a sleep laboratory, carryover, and time-related changes still need consideration. The design name alone does not eliminate those concerns.
The different sleep outcomes also should not be combined into a generic claim of deeper sleep. Stage-two sleep, slow-wave sleep, total sleep time, and waking after sleep onset describe different aspects of a night. The peptide's name does not establish which of those measures changes.
Clinical usefulness requires more than an isolated statistical comparison. A meaningful improvement would need adequate magnitude, consistency, precision, and relevance to how patients sleep and function. Short-term laboratory observations do not establish durable symptom relief.
This report is a caution against selecting the significant sleep-stage result while omitting the baseline imbalance and neutral outcomes. It supplies limited short-term insomnia evidence, not a reliable demonstration that DSIP improves deep sleep or a justification for unsupervised treatment.
Frequently asked questions
Was sleep measured objectively?
Yes, with polysomnography.
Was placebo included?
Yes.
Were all numerical improvements significant?
No.
Were some differences present before treatment?
Yes.
Did slow-wave sleep improve?
It was not modified in the reported findings.
Does the name DSIP prove a deep-sleep effect?
No.
What is the key lesson?
Interpret treatment-period differences in light of baseline and study period.